Household antibiotic use in Malawi: a cross-sectional survey from urban and peri-urban Blantyre

Eleanor E MacPherson^{1,2}, John Mankhomwa¹, Justin Dixon³, Raymond Pongolani¹, Mackwellings Phiri¹, Nicholas Feasey^{1,2}, Thomasena O'Byrne^{1,2}, Rachel Tolhurst², Peter MacPherson^{1,2,3,4}

Affiliations

- 1. Malawi-Liverpool-Wellcome Programme, Malawi
- 2. Liverpool School of Tropical Medicine, UK
- 3. London School of Hygiene & Tropical Medicine, UK
- 4. University of Glasgow UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Abstract

2 Background

- 3 Antimicrobial resistance (AMR) is a significant threat to public health. Use of antibiotics,
- 4 particularly in contexts where weaker regulatory frameworks make informal access easier,
- 5 has been identified as an important driver of AMR. However, knowledge is limited about the
- 6 ways antibiotics are used in communities in sub-Saharan Africa.

7 Methods

- 8 Between April and July 2021, we undertook a cross-sectional survey of community antibiotic
- 9 use practices in Blantyre, Malawi. We selected two densely-populated neighbourhoods
- 10 (Chilomoni and Ndirande) and one peri-urban neighbourhood (Chileka) and undertook
- 11 detailed interviews to assess current and recent antibiotic use, supported by the innovative
- 12 "drug bag" methodology. Regression modelling investigated associations with patterns of
- 13 antibiotic recognition.
- 14 Results

15 We interviewed 217 households with a total of 1051 household members. The number of 16 antibiotics recognised was significantly lower among people with poorer formal health care 17 access (people with unknown HIV status vs. HIV-negative, adjusted odds ratio [aOR]: 0.76, 95% CI: 0.77-.099) and amongst men (aOR: 0.83, 95% CI: 0.69-0.99), who are less likely to 18 19 support healthcare-seeking for family members. Reported antibiotic use was mostly limited 20 to a small number of antibiotics (amoxicillin, erythromycin and cotrimoxazole), with current 21 antibiotic use reported by 67/1051 (6.4%) and recent use (last 6 months) by 440/1051 22 (41.9%).

23 Conclusions

- 24 Our findings support the need for improved access to quality healthcare in urban and peri-
- 25 urban African settings to promote appropriate antibiotic use and limit the development and
- 26 spread of AMR.

28 Introduction

29	Drug resistant infections are increasing worldwide and there is global consensus on the
30	need for urgent action to address antimicrobial resistance (AMR). ¹ Optimising the use of
31	antibiotics is one of the central pillars of the WHO global action plan to address AMR. ² The
32	ramifications of AMR are being more acutely felt in low-and-middle-income countries
33	(LMICs), where there is a higher burden of infectious diseases and health systems are
34	weaker. ³ In low-income contexts where routine diagnostic microbiology facilities are scarce,
35	data on the epidemiology and burden of AMR is limited. ^{4–6}
36	
37	In the past two decades, academic and policy research has shown a substantially increased
38	use of antibiotics in LMICs. ^{7,8} Due to contextual factors including weaker regulatory
39	frameworks and more fragile health systems, antibiotics are often bought over-the-counter,
40	or obtained through informal networks. ^{9–11} However, research conducted in LMICs has
41	demonstrated that antibiotic use practices, including self-medication, are heterogeneous. ^{12–}
42	¹⁴ Do and colleagues (2021) undertook a survey in six countries in Asia and Africa, and found
43	substantial differences in self-medication of antibiotics, with rates lower in Mozambique
44	(8·0%) and South Africa (1·2%) than in Bangladesh (45·7%) and Ghana (36·1%). ¹⁴ Torres and
45	colleagues (2020) did a systematic scoping review of self-medication with antibiotics in 10
46	low- and middle-income countries, and found a prevalence of self-medication in the
47	preceding year that ranged from 8.1% to 93% across countries. ¹³ Both these studies found
48	that factors shaping self-medication were complex and included access to, and cost and
49	quality of care at health care facilities. ^{13,14} The diversity in the prevalence of self-medication
50	of antibiotics in different countries underscores the need for accurate national data to guide
51	antibiotic use and AMR policy and practice.

53	Global antibiotic consumption assessments have primarily relied on pharmaceutical sales
54	records, but this data is frequently unavailable or unreliable, especially in the African
55	region. ^{15–17} In LMICs, most academic research has been conducted in secondary or tertiary
56	care facilities. While researchers are increasingly investigating antibiotic use in primary
57	health care and community contexts, ^{12,16,18} there remain significant gaps in knowledge on
58	antibiotic use practices in community settings, with knowledge particularly limited in
59	countries in Southern and Eastern Africa. ^{13,14} Given the role reduction in antibiotic use (ABU)
60	is expected to play in reducing AMR, generating robust ABU surveillance data is a necessary
61	first step to inform context-specific interventions. ¹⁹ This paper aimed to generate data on
62	current antibiotic use in three residential areas in Blantyre, Malawi.

63 Materials and Methods

64 Ethics statement

- 65 Ethical approval was obtained from the College of Medicine Research Ethics Committee,
- 66 Malawi (approval number: P06/182429) and London School of Hygiene and Tropical
- 67 Medicine Research Ethics Committee (approval number: 14617). Permission to work in the
- 68 study communities was granted by the Blantyre District Health Officer. All participants
- 69 provided written informed consent to participate.
- 70
- 71 Study Design and Population
- 72


73 Data were collected between April and July 2021. We undertook a cross-sectional survey in 74 two densely-populated neighbourhoods (Chilomoni and Ndirande) and one peri-urban 75 neighbourhood (Chileka) in Blantyre, Malawi. Blantyre is a major commercial centre located 76 in the Southern Region of Malawi. The total population of Blantyre District was estimated to be approximately 1 million people in the 2018 Malawi National Census²⁰, and adult HIV 77 prevalence is estimated to be 18%²¹. Chilomoni and Ndirande are well-established urban 78 79 neighbourhoods, with poor access to municipal services, and high rates of household 80 poverty. Chileka is located on the periphery of Blantyre and is characterised by a mixture of 81 recently established peri-urban households and households engaged in subsistence farming.

82

Participants eligible to take part in the survey were adults (aged 18 years or older) resident
in households in either Chilomoni, Chileka, or Ndirande. We excluded households where
there was no adult available to complete questionnaires, or where the household head
declined consent to participate.

- The unit of sampling was the household. To establish a household sampling frame for 88 89 Chilomoni and Ndirande, we obtained neighbourhood boundaries and used georeferenced 90 household data from a previous population census of these neighbourhoods conducted as 91 part of a cluster-randomised trial of TB and HIV interventions in 2015 (Figure 1). Households 92 were randomly selected within each neighbourhood, with a replacement list for when 93 households declined participation or were not identified. As Chileka was not part of the 2015 trial census, we selected random sets of GPS coordinates from within the 94 95 neighbourhood boundaries.
- 96

97 Figure 1: Location of households sampled for interview



99 Procedures

100	Using GPS coordinates of randomly-selected households in Chilomoni and Ndirande, study
101	fieldworkers navigated to selected households; in Chileka, they navigated to selected
102	locations using GPS coordinates, and identified the nearest household to this point. After
103	identifying the household head and obtaining informed written consent, the fieldworker
104	administered a questionnaire to record demographic and socio-economic characteristics of
105	the household and household head. Data were collected using ODK Collect running on study
106	tablets and uploaded securely in real-time to the Data Server at the London School of
107	Hygiene and Tropical Medicine.
108	
109	To evaluate household heads' understanding and use of antibiotics, the fieldworker used
110	the "drug bag" method, which comprised of a bag of antibiotics packages and tablets
111	assembled by the team through visiting formal and informal access points for medicines. ²²
112	We adapted this method from anthropological studies we have undertaken exploring
113	medicine use practices in Southern and Eastern Africa. ²² The drug bag was used to facilitate
114	questions to the household head on which antibiotics they recognised (i.e. had ever seen or
115	heard about before), whether antibiotics were currently being used in the household, and
116	more generally about antibiotic use practices in the household (see Supplementary
117	Material). The drug bag helped to overcome linguistic barriers, as 'antibiotic' is a category of
118	medicines that is not readily understood in Malawi.
119	
120	
121	

122

Page 8 of 24

123 Statistical Methods

We initially set out to survey 75 households in each of two of the study neighbourhoods
(Chilomoni and Ndirande), and subsequentially added the third neighbourhood (Chileka) to
allow comparison with this peri-urban neighbourhood.

127

128	We summarised household, and household head characteristics by study neighbourhood
129	using counts and percentages, and means and standard deviations, and compared between
130	groups using Chi-square tests and Fisher's exact tests for categorical data, and Student's T
131	test for continuous data. We used a p-value threshold of <0.05 to define a statistically-
132	significant difference between neighbourhoods. Our main study outcomes were antibiotic
133	use and recognition patterns. To investigate this, we summarised the number of household
134	members who reported currently using, or having recently used (within the last 6-months)
135	each antibiotic, and the number of antibiotics recognised by household respondents. To
136	estimate the percentage of the total study population who used and recognised each
137	antibiotic, we divided antibiotics within each category by the total numbers of household
138	members, calculated binomial exact confidence intervals, and compared between study
139	sites. We constructed a multivariable Poisson regression model to investigate associations
140	with the number of antibiotics recognised by household respondents. Analysis was
141	conducted using R v4.1.1 (R Foundation for Statistical Computing, Vienna).
142	
143	Data and code to reproduce analysis are available at DOI10.17605/OSF.IO/58EKN
144	

146 Results

- 147
- 148 In total, 217 households were interviewed and included in this analysis (Table 1). A total of
- 149 1051 household members were identified by respondents. Numbers of household residents
- 150 ranged between 1 and 13, with a median of 5 (interquartile range: 3-6). Numbers of
- 151 household residents were similar between the three study sites (p=0.771).
- 152

153Table 1: Characteristics of households and household respondents, by study site

	Chileka (N=74)	Chilomoni (N=67)	Ndirande (N=76)	Total (N=217)	P-value
lousehold residents otal (median per household, IQR)	355 (4, 3-6)	321 (5, 4-6)	375 (5, 3-6)	1051	0.771
Duration residing in site					0.213
Less than one year	2 (2.7%)	6 (9.0%)	7 (9.2%)	15 (6.9%)	
More than one year	72 (97.3%)	61 (91.0%)	69 (90.8%)	202 (93.1%)	
lousehold respondent male	16 (21.6%)	17 (25.4%)	10 (13.2%)	43 (19.8%)	0.167
lousehold respondent age, Mean (SD)	38 (16)	38 (12)	37 (13)	38 (14)	0.657
lousehold respondent occupation					< 0.001
Paid domestic worker	0 (0.0%)	3 (4.5%)	4 (5.3%)	7 (3.2%)	
Paid employee	5 (6.8%)	4 (6.0%)	4 (5.3%)	13 (6.0%)	
Self employed	21 (28.4%)	27 (40.3%)	30 (39.5%)	78 (35.9%)	
Student	1 (1.4%)	1 (1.5%)	1 (1.3%)	3 (1.4%)	
Unemployed	32 (43.2%)	31 (46.3%)	37 (48.7%)	100 (46.1%)	
Other	15 (20.3%)	1 (1.5%)	0 (0.0%)	16 (7.4%)	
lectricity in dwelling	6 (8.1%)	50 (74.6%)	58 (76.3%)	114 (52.5%)	< 0.001
ood sufficient to meet needs	38 (51.4%)	38 (56.7%)	43 (56.6%)	119 (54.8%)	0.759
elf-rated household poverty					< 0.001
1 = poorest in neighbourhood	8 (10.8%)	5 (7.5%)	1 (1.3%)	14 (6.5%)	
2	36 (48.6%)	19 (28.4%)	24 (31.6%)	79 (36.4%)	
3	27 (36.5%)	29 (43.3%)	45 (59.2%)	101 (46.5%)	
4	3 (4.1%)	14 (20.9%)	6 (7.9%)	23 (10.6%)	
5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
6 = richest in neighbourhood	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
lousehold respondent highest education le completed	evel				0.044
Missing	1	0	0	1	
Never been to school	5 (6.8%)	3 (4.5%)	3 (3.9%)	11 (5.1%)	
Primary	43 (58.9%)	22 (32.8%)	29 (38.2%)	94 (43.5%)	
Secondary completed MSCE	2 (2.7%)	7 (10.4%)	8 (10.5%)	17 (7.9%)	
Secondary no MSCE	22 (30.1%)	32 (47.8%)	35 (46.1%)	89 (41.2%)	
Higher	1 (1.4%)	3 (4.5%)	1 (1.3%)	5 (2.3%)	
lousehold respondent literate	58 (78.4%)	61 (91.0%)	63 (82.9%)	182 (83.9%)	0.119


	Chileka (N=74)	Chilomoni (N=67)	Ndirande (N=76)	Total (N=217)	P-value
Household respondent self-rated general health					0.538
Missing	1	0	2	3	
Very poor	2 (2.7%)	0 (0.0%)	0 (0.0%)	2 (0.9%)	
Poor	7 (9.6%)	5 (7.5%)	5 (6.8%)	17 (7.9%)	
Fair	20 (27.4%)	19 (28.4%)	23 (31.1%)	62 (29.0%)	
Good	31 (42.5%)	27 (40.3%)	25 (33.8%)	83 (38.8%)	
Very good	13 (17.8%)	16 (23.9%)	21 (28.4%)	50 (23.4%)	
Household respondent marital status					0.307
Divorced	4 (5.4%)	3 (4.5%)	6 (7.9%)	13 (6.0%)	
Living together as if married	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (0.5%)	
Married	50 (67.6%)	49 (73.1%)	59 (77.6%)	158 (72.8%)	
Married but not living together	2 (2.7%)	0 (0.0%)	0 (0.0%)	2 (0.9%)	
Never married	7 (9.5%)	3 (4.5%)	3 (3.9%)	13 (6.0%)	
Polygamous marriage	0 (0.0%)	0 (0.0%)	2 (2.6%)	2 (0.9%)	
Separated	3 (4.1%)	2 (3.0%)	1 (1.3%)	6 (2.8%)	
Widowed	8 (10.8%)	9 (13.4%)	5 (6.6%)	22 (10.1%)	
Household respondent previously lost spouse to death					0.704
Missing	1	1	0	2	
Yes	12 (16.4%)	12 (18.2%)	10 (13.2%)	34 (15.8%)	
Household respondent ever tested for HIV previously	68 (91.9%)	64 (95.5%)	70 (92.1%)	202 (93.1%)	0.639
Household respondent HIV status					0.131
HIV-negative	62 (83.8%)	57 (85.1%)	58 (76.3%	177 (81.6%)	
HIV-positive	4 (5.4%)	7 (10.4%)	13 (17.1%)	24 (11.1%)	
Unknown	8 (10.8%)	3 (4.5%)	5 (6.6%)	16 (7.4%)	
Household respondent taking ART (if HIV- positive)	4 (100%)	7 (100%)	13 (100%)	24 (100%)	1.000

¹⁵⁵

156 The majority of household respondents were female (80.2%), and the mean respondent age 157 was 38 years. Household and household respondent characteristics were similar in 158 Chilomoni and Ndirande, but there were substantial differences between these 159 neighbourhoods and Chileka. Whereas in Ndirande (76.3%) and Chilomoni (74.6%) most 160 households had electricity supplied to the dwelling, in Chileka only 8.1% had electricity 161 (p<0.001). 78.4% of household respondents in Chileka reported that they were literate, 162 compared to 91.0% in Chilomoni and 82.9% in Ndirande (p=0.119). Reported coverage of 163 HIV testing was very high and similar across neighbourhoods, with 93.1% of household

164	respondents reporting having ever previously tested for HIV (p=0.639 for comparison
165	between sites). Self-reported HIV-positive status was 11.1% overall, and was substantially
166	(but not statistically significantly) lower in Chileka (5.4%) compared to Chilomoni (10.4%)
167	and Ndirande (17.1%), p=0.131. Antiretroviral therapy coverage was 100% among HIV-
168	positive respondents across all three sites.
169	
170	Antibiotic recognition
171	Using the drug bag method, household respondents recognised a median of five antibiotics
172	(IQR: 3-6). The median number of antibiotics recognised in Chileka (4, IQR: 3-6) was slightly
173	lower than in Chilomoni (5, IQR:3-6) or Ndirande (5, IQR: 4-6.25), but this was not
174	statistically significant (p=0.1176). The most common antibiotics recognised overall by
175	household respondents were: amoxicillin tablets (202/217, 93.1%, 95% CI: 88.9-96.1%);
176	cotrimoxazole tablets (184/217, 84.8%, 95% CI: 79.3-89.3%); and amoxicillin suspension
177	(94/217, 43.3%, 95% CI: 36.6-50.2%). Patterns of antibiotic recognition were broadly similar
178	between the three study sites (Figure 2).

179 Figure 2: Household respondent antibiotic recognition, by study site



181

182 Associations with recognition of antibiotics

- 183 In univariable regression analysis, household respondents from Ndirande (relative risk [RR]:
- 1.18, 95% CI: 1.02-1.36, compared to Chileka), and from larger households (RR: 1.03, 95% CI: 184
- 1.00-1.06 per person increase in household size) recognised a significantly greater number 185
- 186 of antibiotics (Table 2). Respondents with unknown HIV status (RR: 0.76, 95% CI: 0.58-0.98)
- 187 and male household respondents recognised significantly fewer antibiotics than women
- 188 (0.88, 95% CI: 0.75-1.03) although this was not statistically significant. In multivariable
- 189 regression, male sex (RR: 0.83, 95% CI: 0.69-0.99) and having unknown HIV status (RR: 0.76,
- 190 95% CI: 0.57-0.99) were significantly associated with recognition of fewer antibiotics.
- 191

192

193

Variable	Univariate relative risk	95% confidence interval	Multivariable relative risk	95% confidence interval
Site				
Chileka	Ref		Ref	
Chilomoni	1.15	0.99-1.34	1.10	0.94-1.28
Ndirande	1.18	1.02-1.36	1.09	0.94-1.27
Respondent sex				
Female	Ref		Ref	
Male	0.88	0.75-1.03	0.83	0.69-0.99
Respondent age (per year)	1.00	1.00-1.01	1.00	1.00-1.01
Household self-rated poverty status	S			
Very poor	Ref		Ref	
Poor	0.97	0.75-1.28	0.99	0.76-1.31
Somewhat poor	1.22	0.95-1.59	1.22	0.94-1.61
Somewhat rich	1.12	0.83-1.53	1.17	0.85-1.62
Respondent HIV status				
HIV-negative	Ref		Ref	
HIV-positive	1.11	0.92-1.32	1.03	0.85-1.25
HIV status unknown	0.76	0.58-0.98	0.76	0.57-0.99

1.00-1.06

0.93-1.30

194 195 Number of household members

Respondent illiterate

Respondent literate

Respondent literacy

1.03

Ref

1.10

0.99-1.05

0.85-1.22

1.02

Ref

1.01

196

197 Antibiotic use

- 198 Of the 1051 household members, a total of 67 (6.4%, 95% CI: 5.0-8.0%) were reportedly
- 199 currently taking one of the antibiotics identified within the drug bag (Table 3). The bag
- 200 included multiple versions of the same antibiotics (active ingredients) to facilitate
- 201 recognition. Estimates of household members' current antibiotic use were similar between
- 202 Chileka (22/355, 6.2%, 95% CI: 3.9-9.2%), Chilomoni (20/321, 6.3%, 95% CI: 3.8-9.5%), and
- 203 Ndirande (25/375, 6.7%, 4.4-9.7%). Only five antibiotics (counted by active ingredient) were
- 204 identified as being currently taken by household members (Table 2). The antibiotic
- 205 formulation most commonly reported as currently used was cotrimoxazole tablets
- 206 (39/1051, 3.7%, 95% CI: 2.7-5.0%), followed by amoxicillin tablets (13/1051, 1.2%, 95% CI:
- 207 0.7-2.1%), erythromycin tablets (5/1051, 0.5%, 95% CI: 0.2-1.1%) and amoxicillin suspension
- 208 (5/1051, 0.5%, 95% CI: 0.2-1.1%).

Table 3: Antibiotic use by household members 209

210

Antibiotic	Chileka (N=355) n (%, 95%Cl)	Chilomoni (N=321) n (%, 95%Cl)	Ndirande (N=375) n (%, 95%Cl)
Current use	· · ·	· · · ·	
Amoxicillin (Suspension)	1 (0.3%, 0.0%-1.6%)	1 (0.3%, 0.0%-1.7%)	3 (0.8%, 0.2%-2.3%)
Amoxicillin (Tablets)	4 (1.1%, 0.3%-2.9%)	5 (1.6%, 0.5%-3.6%)	4 (1.1%, 0.3%-2.7%)
Chloramphenicol (Tablets)		1 (0.3%, 0.0%-1.7%)	
Cotrimoxazole (Tablets)	13 (3.7%, 2.0%-6.2%)	10 (3.1%, 1.5%-5.7%)	16 (4.3%, 2.5%-6.8%)
Doxycycline (Tablets)	1 (0.3%, 0.0%-1.6%)	1 (0.3%, 0.0%-1.7%)	
Erythromycin (Suspension)			2 (0.5%, 0.1%-1.9%)
Erythromycin (Tablets)	3 (0.8%, 0.2%-2.4%)	2 (0.6%, 0.1%-2.2%)	
Used last 6 months			
Amoxicillin (Suspension)	11 (3.1%, 1.6%-5.5%)	7 (2.2%, 0.9%-4.4%)	20 (5.3%, 3.3%-8.1%)
Amoxicillin (Tablets)	44 (12.4%, 9.2%-16.3%)	39 (12.1%, 8.8%-16.2%)	43 (11.5%, 8.4%-15.1%)
Amoxicillin/clavulanic acid (Tablets)		2 (0.6%, 0.1%-2.2%)	
Ampicillin (Tablets)			2 (0.5%, 0.1%-1.9%)
Benzathine Penicillin (Injectable)	1 (0.3%, 0.0%-1.6%)		
Benzylpenicillin (Injectable)		1 (0.3%, 0.0%-1.7%)	1 (0.3%, 0.0%-1.5%)
Cefalexin (Tablets)		1 (0.3%, 0.0%-1.7%)	1 (0.3%, 0.0%-1.5%)
Chloramphenicol (Eye/Ear)	1 (0.3%, 0.0%-1.6%)	2 (0.6%, 0.1%-2.2%)	4 (1.1%, 0.3%-2.7%)
Chloramphenicol (Tablets)		2 (0.6%, 0.1%-2.2%)	2 (0.5%, 0.1%-1.9%)
Ciprofloxacin (Eye)	2 (0.6%, 0.1%-2.0%)	3 (0.9% <i>,</i> 0.2%-2.7%)	1 (0.3%, 0.0%-1.5%)
Ciprofloxacin (Tablets)	2 (0.6%, 0.1%-2.0%)	1 (0.3%, 0.0%-1.7%)	1 (0.3%, 0.0%-1.5%)
Clindamycin (Injectable)			1 (0.3%, 0.0%-1.5%)
Cloxacillin (Suspension)	1 (0.3%, 0.0%-1.6%)		
Cloxacillin (Tablets)	1 (0.3%, 0.0%-1.6%)		
Cotrimoxazole (Suspension)	1 (0.3%, 0.0%-1.6%)	1 (0.3%, 0.0%-1.7%)	1 (0.3%, 0.0%-1.5%)
Cotrimoxazole (Tablets)	47 (13.2%, 9.9%-17.2%)	30 (9.3%, 6.4%-13.1%)	39 (10.4%, 7.5%-13.9%)
Doxycycline (Tablets)	6 (1.7%, 0.6%-3.6%)	7 (2.2%, 0.9%-4.4%)	12 (3.2%, 1.7%-5.5%)
Erythromycin (Suspension)	3 (0.8% <i>,</i> 0.2%-2.4%)		1 (0.3%, 0.0%-1.5%)
Erythromycin (Tablets)	9 (2.5%, 1.2%-4.8%)	11 (3.4%, 1.7%-6.0%)	8 (2.1%, 0.9%-4.2%)
Gentamicin (Injectable)		1 (0.3%, 0.0%-1.7%)	
Gentamicin (Eye/Ear)	1 (0.3%, 0.0%-1.6%)	3 (0.9% <i>,</i> 0.2%-2.7%)	4 (1.1%, 0.3%-2.7%)
Levofloxacin (Tablets)		1 (0.3%, 0.0%-1.7%)	
Metronidazole (Suspension)	4 (1.1%, 0.3%-2.9%)	3 (0.9%, 0.2%-2.7%)	7 (1.9%, 0.8%-3.8%)
Metronidazole (Tablets)	9 (2.5%, 1.2%-4.8%)	9 (2.8%, 1.3%-5.3%)	13 (3.5%, 1.9%-5.9%)
Phenoxymethylpenicillin (Tablets)	1 (0.3%, 0.0%-1.6%)	1 (0.3%, 0.0%-1.7%)	3 (0.8%, 0.2%-2.3%)
Tetracycline (Eye)	1 (0.3%, 0.0%-1.6%)	2 (0.6%, 0.1%-2.2%)	4 (1.1%, 0.3%-2.7%)

211 Denominators are all reported household members, by site. Binomial exact 95% confidence intervals.

212 Where cells are blank, household heads reported no use/use in last 6-months of this antibiotic by household members. 213

Household respondents reported that 440 of the 1051 household members (41.9%) had 214

215 taken an antibiotic in the last 6-months. The antibiotic formulations that had been

216 reportedly most frequently taken in the preceding 6-months were: amoxicillin tablets

217 (126/1051, 12.0%, 95% CI: 10.1%-14.1%); cotrimoxazole tablets (116/1051, 11.0%, 95% CI:

218 9.2-13.1%); and amoxicillin suspension (38/1051, 3.6%, 95% CI: 2.6-4.9%). Patterns of

219 reported antibiotic use in the preceding 6-months were broadly similar between the three

220 study sites.

221 Discussion

222	
223	The main findings of this detailed cross-sectional survey of community antibiotic use
224	practices in Blantyre Malawi were that current antibiotic use was (67/1051, 6.4%) and
225	recent use (last 6 months) was (440/1051, 41.9%). Both current and recent antibiotic use
226	were limited to a small number of antibiotic formualtions, with amoxicillin and
227	cotrimoxazole being the most frequently recognised and used. Both antibiotics are classified
228	as "access" on the WHO's Access, Watch, Reserve (AWaRe) list, meaning they are commonly
229	used to treat infections and should be clinically available at all times ²³ . In contexts such as
230	Malawi, cotrimoxazole is commonly used for chemoprophylaxis for people living with HIV,
231	and with HIV prevalence in the study populations being high, it is not surprising that this was
232	one of the most commonly used and recognised antibiotic. In contrast, the number of
233	antibiotics recognised was significantly lower among people less likely to access formal
234	health services (such as people with unknown HIV status, a strong indicator of delayed
235	healthcare seeking and poor access where testing is widely available), and men, who
236	frequently do not participate in care-seeking activities for families.
237	
238	Taken together, these findings suggest that, contrary to popular narratives, use of a wide
239	range of antibiotics and antibiotics on the watch or reserve lists was not widespread in
240	these urban and periurban African settings; rather access to a wide range of antibiotics is
241	likely to be limited for the majority of the population, and potentially not a major
242	contributor to so-called "antibiotic overuse". Nevertheless, antibiotics such as
243	cotrimoxazole, amoxicillin, and erythromycin have broad spectrum action, and dependence
244	on these antibiotics for community management of illness is associated with generation of
245	resistance. Therefore, ABU and AMR guidance must recognise the healthcare and

246 sociological context within which recommendations are made; improvements in universal healthcare access (including treatment of infection) should be accompanied by high quality 247 248 surveillance and antibiotic use data, supported by interrogation of social narratives around 249 the determinants of antibiotic use. 250 251 In Malawi and similar settings in Southern and Eastern African countries, primary health care facilities are an important source of community care, with services provided free, ²⁴ but 252 253 delivered under severe resource constraints with high rates of stockouts of many essential medicines.^{25,26} International donor programmes play a significant role in funding services, 254 and infectious diseases have received comparably more resources.²⁷ The provision of 255 256 cotrimoxazole by the HIV programme at primary care clinics may explain why it is well 257 recognised and used within households.²⁵ A multi-site study exploring household antibiotic 258 use in Zimbabwe, Malawi and Uganda identified differences in the profile of ABU, with 259 cotrimoxazole being the most frequently used in rural Malawi, amoxicillin in Harare, Zimbabwe, and metronidazole within informal settlements in Uganda.²⁸ Most differences in 260 261 use reflected differences in the configuration of the health system and antibiotic supplies.

262

In Malawi, gender power relations shape household care seeking practices, with men often presenting at health care facilities critically ill, and having delayed diagnosis of diseases of major public health importance, particularly HIV and tuberculosis.²⁹ Women spend considerably more time than men seeking care and supporting household members to seek care.³⁰ These factors are likely to explain why women had better recognition and use of antibiotics. While government health care facilities provide care without user fees, care seeking incurs costs for transportation and loss of time from other livelihood activities.³¹

270	Improving access and removing economic barriers to care seeking, are likely to be important
271	interventions to improve the community management of febrile illness, both to improve
272	recognition of severe illness requiring antibiotics with referral to hospital where required,
273	and to restrict unnecessary ABU.
274	
275	Global public engagement campaigns to improve awareness of antimicrobial resistance have
276	focused predominantly on communicating the need to stop people from indiscriminately
277	using antibiotics with insufficient attention paid to the issues of access. ³² Our findings
278	demonstrate frequent use of a very limited number of antibiotic formulations in the
279	preceding six months, however in a context where febrile illness is common and
280	presentation to health care facilities is late, and diagnostics are few, this may represent
281	appropriate prescribing. Indeed, this may instead speak to the need to improve access to
282	and quality of health care services, not limit access, particularly for the most economically
283	disadvantaged groups.
284	
285	The limitations of this study include the potential for social desirability bias, whereby
286	household respondents may state that they recognised or used antibiotics to meet
287	interviewer's expectations. We mitigated against this by using our innovative and previously
288	validated "drug bag" methodology and experienced field interviewers. The drug bag uses a
289	wide range of antibiotics available in the community; however it is possible that we did not
290	include some important formulations, or that packaging designs have changed, limiting
291	recognition. The concept of an "antibiotic" is not well understood in Malawi and has no
292	specific Chichewa word, potentially hindering accurate recall of use and recognition. We
293	randomly sampled households from a community sampling frame to minimise sampling

bias; nevertheless, women were over-represented, perhaps because men may not have
been available for interview, or at work. We may therefore have underestimated antibiotic
use and recognition.

297

- 298 In conclusion, we found patterns of current and recent antibiotic use and recognition among
- 299 randomly-sampled household members in Blantyre, Malawi to be limited to a small number
- 300 of broads-spectrum antibiotic formulations. People known to have poorer access to
- 301 healthcare reported recognising fewer antibiotics. So-called "antibiotic overuse" –
- 302 specifically of antibiotics on the watch list is unlikely to be a major driver of antimicrobial
- 303 resistance and drug resistance infections in this and similar settings. Rapidly reducing
- 304 generation of antibiotic resistance and drug resistant infection in low-income settings in
- 305 Africa will require a shift of focus, away from narratives that blame people in precarious
- 306 living conditions for "antibiotic overuse" and instead towards holistic approaches that
- 307 address the underlying systemic drivers of AMR, whilst recognising and supporting antibiotic
- 308 access within well-functioning health systems.

309

310

311 Acknowledgements

We are grateful to all study participants who took part in this study and to the DRUMConsortium.

314

315 Funding

- 316 This study was funded by AMR Cross-Council Initiative through a grant from the Medical
- 317 Research Council MR/S004793/1. MLW is funded by Wellcome Asia and Africa Programme
- 318 Grant 206545/Z/17/Z. PM is funded by Wellcome (206575/Z/17/Z). For the purpose of open
- access, the author has applied a CC BY public copyright licence to any Author Accepted
- 320 Manuscript version arising from this submission.
- 321

322 References

- WHO,. New report calls for urgent action to avert antimicrobial resistance crisis. World
 Health Organization. Published 2019. Accessed July 27, 2021.
- https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to avert-antimicrobial-resistance-crisis
- WHO,. WHO: Global Action Plan on Antimicrobial Resistance. World Health
 Organization; 2015. Accessed August 11, 2020. http://www.who.int/antimicrobial resistance/publications/global-action-plan/en/
- Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, Villegas MV, Gould I, Levy Hara
 G. Antibiotic stewardship in low- and middle-income countries: the same but different?
 Clinical Microbiology and Infection. 2017;23(11):812-818. doi:10.1016/j.cmi.2017.07.010
- Jasovský D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance—a threat to the
 world's sustainable development. *Upsala Journal of Medical Sciences*. 2016;121(3):159 164. doi:10.1080/03009734.2016.1195900
- Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E,
 Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W,
 Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R,
 Wright GD, Brown ED, Cars O. Antibiotic resistance-the need for global solutions. *Lancet Infect Dis.* 2013;13(12):1057-1098. doi:10.1016/S1473-3099(13)70318-9
- Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, Lugova H, Dhingra S,
 Sharma P, Islam S. Surveillance of antimicrobial resistance in low-and middle-income
 countries: a scattered picture. *Antimicrobial Resistance & Infection Control*.
 2021;10(1):1-19.
- Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, Goossens H,
 Laxminarayan R. Global increase and geographic convergence in antibiotic consumption
 between 2000 and 2015. *Proceedings of the National Academy of Sciences*.
 2018;115(15):E3463-E3470.
- Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R.
 Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical
 sales data. *The Lancet infectious diseases*. 2014;14(8):742-750.
- WHO,. Antibiotic resistance: Key facts. World Health Organization. Published 2020.
 Accessed June 24, 2020. https://www.who.int/news-room/fact-sheets/detail/antibiotic resistance
- 356 10. Sartelli M, C Hardcastle T, Catena F, Chichom-Mefire A, Coccolini F, Dhingra S, Haque M,
 357 Hodonou A, Iskandar K, Labricciosa FM. Antibiotic use in low and middle-income
 358 countries and the challenges of antimicrobial resistance in surgery. *Antibiotics*.
 359 2020;9(8):497.

- 360 11. Wilkinson A, Ebata A, MacGregor H. Interventions to Reduce Antibiotic Prescribing in
 361 LMICs: A Scoping Review of Evidence from Human and Animal Health Systems.
- 362 *Antibiotics*. 2018;8(1):2. doi:10.3390/antibiotics8010002
- 363 12. Yeika EV, Ingelbeen B, Kemah B, Wirsiy FS, Fomengia JN, Van der Sande MA.
 364 Comparative assessment of the prevalence, practices and factors associated with self365 medication with antibiotics in Africa. *Tropical Medicine & International Health*.
 366 2021;26(8):862-881.
- 367 13. Torres N, Chibi B, Middleton L, Solomon V, Mashamba-Thompson T. Evidence of factors
 368 influencing self-medication with antibiotics in low and middle-income countries: a
 369 systematic scoping review. *Public health*. 2019;168:92-101.
- 14. Do NT, Vu HT, Nguyen CT, Punpuing S, Khan WA, Gyapong M, Asante KP, Munguambe K,
 Gómez-Olivé FX, John-Langba J. Community-based antibiotic access and use in six lowincome and middle-income countries: a mixed-method approach. *The Lancet Global Health*. 2021;9(5):e610-e619.
- 374 15. Hamers RL, van Doorn HR. Antibiotic consumption in low-income and middle-income
 375 countries. *The Lancet Global Health*. 2018;6(7):e732.
- Sulis G, Adam P, Nafade V, Gore G, Daniels B, Daftary A, Das J, Gandra S, Pai M.
 Antibiotic prescription practices in primary care in low- and middle-income countries: A
 systematic review and meta-analysis. Kruk ME, ed. *PLoS Med*. 2020;17(6):e1003139.
 doi:10.1371/journal.pmed.1003139
- 17. Allwell-Brown G, Hussain-Alkhateeb L, Sewe MO, Kitutu FE, Strömdahl S, Mårtensson A,
 Johansson EW. Determinants of trends in reported antibiotic use among sick children
 under five years of age across low-income and middle-income countries in 2005-17: a
 systematic analysis of user characteristics based on 132 national surveys from 73
 countries. International Journal of Infectious Diseases. Published online 2021.
- 18. Frost I, Kapoor G, Craig J, Liu D, Laxminarayan R. Status, challenges and gaps in
 antimicrobial resistance surveillance around the world. *Journal of Global Antimicrobial Resistance*. Published online 2021.
- 19. Kirchhelle C, Atkinson P, Broom A, Chuengsatiansup K, Ferreira JP, Fortané N, Frost I,
 Gradmann C, Hinchliffe S, Hoffman SJ, Lezaun J, Nayiga S, Outterson K, Podolsky SH,
 Raymond S, Roberts AP, Singer AC, So AD, Sringernyuang L, Tayler E, Rogers Van Katwyk
 S, Chandler CIR. Setting the standard: multidisciplinary hallmarks for structural,
 equitable and tracked antibiotic policy. *BMJ Glob Health*. 2020;5(9):e003091.
 doi:10.1136/bmjgh-2020-003091
- 394 20. National Statistics Office. 2018 Malawi Population and Housing Census. Accessed
 395 September 22, 2021.
- http://www.nsomalawi.mw/index.php%3Foption%3Dcom_content%26view%3Darticle
 %26id%3D226:2018-malawi-population-and-housing-
- 398
 census%26catid%E2%80%89%3D%E2%80%898:reports%26Itemid%E2%80%89%3D%E2

 399
 %80%896

- 400 21. Ministry of Health of Malawi. Malawi Population-based HIV Impact Assessment 2015-401 2016. Published online 2018.
- 22. Dixon J, MacPherson E, Manyau S, Nayiga S, Khine Zaw Y, Kayendeke M, Nabirye C,
 Denyer Willis L, de Lima Hutchison C, Chandler CI. The 'Drug Bag'method: lessons from
 anthropological studies of antibiotic use in Africa and South-East Asia. *Global health action*. 2019;12(sup1):1639388.
- 406 23. WHO, WHO | WHO releases the 2019 AWaRe Classification Antibiotics. WHO. Published
 407 2019. Accessed November 19, 2020.
- 408 http://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification_a
 409 ntibiotics/en/
- 410 24. Makwero MT. Delivery of primary health care in Malawi. *Afr j prim health care fam med*.
 411 2018;10(1). doi:10.4102/phcfm.v10i1.1799
- 412 25. MacPherson EE, Reynolds J, Sanudi E, Nkaombe A, Phiri C, Mankhomwa J, Dixon J,
- Chandler CIR. Understanding antimicrobial resistance through the lens of antibiotic
 vulnerabilities in primary health care in rural Malawi. *Global Public Health*. Published
- 415 online December 21, 2021:1-17. doi:10.1080/17441692.2021.2015615
- 416 26. Wild L, Cammack D. The supply and distribution of essential medicines in Malawi.417 Published online 2013.
- 418 27. Page S. The Development Aid Situation in Malawi. In: *Development, Sexual Cultural* 419 *Practices and HIV/AIDS in Africa*. Springer; 2019:43-60.
- 28. Dixon J, MacPherson EE, Nayiga, S, Manyau S, Nabirye C, Kayendeke M, Sanudi E,
 Nkoambe, A, Mareke, P, Sithole, K, de Lima Hutchison C, Bradley, J, Yeung S, Ferrand R,
 Lal S, Roberts C, Green, E, Denyer Willis, Laurie, Staedke, S, Chandler CIR. A MixedMethods, Multi-Country Analysis of Household Antibiotic use in Malawi, Uganda and
 Zimbabwe. *BMJ Global Health*. 2021;6(e006920).
- 29. Chikovore J, Hart G, Kumwenda M, Chipungu GA, Corbett L. 'For a mere cough, men
 must just chew Conjex, gain strength, and continue working': the provider construction
 and tuberculosis care-seeking implications in Blantyre, Malawi. *Global Health Action*.
 2015;8(1):26292. doi:10.3402/gha.v8.26292
- 30. Yeatman S, Chamberlin S, Dovel K. Women's (health) work: a population-based, crosssectional study of gender differences in time spent seeking health care in Malawi. *PLoS One*. 2018;13(12):e0209586.
- 432 31. Abiiro GA, Grace, MB, De Allegri M. Gaps in universal health coverage in Malawi: A
 433 qualitative study in rural communities. *BMC Health Serv Res.* 2014;14(1):234.
 434 doi:10.1186/1472-6963-14-234
- 435 32. Glover R, Chandler C, Manton J. The benefits and risks of public awareness campaigns:
 436 World Antibiotic Awareness Week in context. *The BMJ Opinion*. Published online 2019.